RxDoctor Payments Data

Samirlal Amin, MD

Family Medicine · North Bergen, NJNPI 1811987928

Payments from drug & device makers

$560in general payments, 2019–2025

Across 15 payments — averaging $37.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Anika Therapeutics, Inc.$132
  • Neurocrine Biosciences, Inc.$116
  • Cardiovascular Systems Inc.$103
  • Novartis$73
  • Abiomed$69
  • Boehringer Ingelheim$14
  • plus $53 from 4 others

What the payments were for

  • Food & beverage$560100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$560 in reported general payments places this provider in the 55th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$225,066
Medicare patients
253
Services billed
2,791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban449$171,253
JardianceEmpagliflozin176$89,347
TradjentaLinagliptin134$64,627
TrulicityDulaglutide66$49,114
JanuviaSitagliptin Phosphate97$44,571
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$41,009
NeuproRotigotine60$29,665
SantylCollagenase Clostridium Hist.52$20,499
EntrestoSacubitril/Valsartan18$18,449
Breo ElliptaFluticasone/Vilanterol43$17,543
Darunavir11$17,430
LinzessLinaclotide26$15,828
FarxigaDapagliflozin Propanediol34$14,988
Divalproex Sodium330$10,578
ProcritEpoetin Alfa19$10,515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$14$153,975310 claims
NovartisEntresto$73$18,44918 claims
Johnson & JohnsonProcrit, Xarelto$14$15,57131 claims
AstraZenecaFarxiga$12$14,98834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in North Bergen

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →